Status:
COMPLETED
A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA
Lead Sponsor:
Gilead Sciences
Conditions:
Pre-exposure Prophylaxis for Prevention of HIV Infection
Eligibility:
All Genders
18+ years
Brief Summary
This is a prospective, 3-year observational study to describe drug utilization in uninfected individuals (UIs) who initiate emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) (Truvada®) for a pre...
Eligibility Criteria
Inclusion
- Key
- Patient/ Uninfected Individual
- Adult (any sex/gender, including transgender) ≥18 years old
- Taking FTC/TDF prescribed for any indication or its components Prescriber
- Possesses an active health care professional license in good standing, with the authority to prescribe prescription medications, either independently (eg, physician) or under legally permissible arrangements for prescribing under physician supervision (eg, Nurse Practitioner or Physician Assistant)
- Practice site is within the USA
- Having prescribed FTC/TDF for a PrEP indication
- Key
Exclusion
- There are no exclusion criteria for individuals or prescribers
- Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
April 22 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 22 2018
Estimated Enrollment :
64186 Patients enrolled
Trial Details
Trial ID
NCT01865799
Start Date
April 22 2013
End Date
January 22 2018
Last Update
March 27 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gilead Sciences, Inc.
Foster City, California, United States, 94404